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Supplementary table 1. Demographic and clinical characteristics of the study participants. 
Data are presented as mean ± SD. 
Baseline Type 2 
Diabetes 
(n=23) 
Controls 
(n=23) 
p-value
Age (years) 64±8 60±10 <0.0001 
Sex (M/F) 12/11 11/12 0.77 
Weight (kg) 90.9±11.1 79.5±8.8 <0.0001 
Height (cm) 167±14 169±5 0.64 
BMI (kg/m2)  32±4 28±3 <0.0001 
Systolic BP (mmHg) 132±8 122±8 0.001 
Diastolic BP (mmHg) 81±7 75±6 0.003 
Duration of diabetes 
(years) 
4.5±2.2 N/A 
HbA1c (mmol/mol) 51.2±11.4 37.2±2.2 <0.0001 
HbA1c (%) 6.8±1.0 5.6±0.2 <0.0001 
Total cholesterol (mmol/l) 4.2±1.0 4.8±0.77 0.014 
Triglyceride (mmol/l) 1.7±0.7 1.34±0.6 0.055 
HDL-cholesterol (mmol/l) 1.1±0.3 1.5±0.4 0.001 
LDL-cholesterol (mmol/l) 2.23±0.8 2.7±0.87 0.051 
CRP (mg/l) 3.0±2.7 5.1±10.3 0.33 
BMI: Body mass index, BP: Blood pressure, HDL-cholesterol: High density lipoprotein 
cholesterol, LDL-cholesterol: Low density lipoprotein cholesterol, CRP: C-reactive protein. 
HbA1c: Hemoglobin A1c 
Supplementary table 2. Student’s t-test values comparing protein levels for baseline versus hypoglycaemia and baseline versus 24-hours post-
hypoglycemia in type 2 diabetes (T2D) and control subjects for the twenty-six proteins included in the analysis. HSP = heat shock protein. 
 Abbreviation 
T2D vs Control 
(Baseline) Baseline vs Hypoglycaemia Baseline vs 24 hours 
Control p-value 
T2D p-
value 
Control p value 
T2D p 
value 
HSP90AA1 HSP90 alpha 0.44 0.88 0.95 0.72 0.85 
HSP90AB1 HSP90 beta 
0.5 
0.26 0.59 0.12 0.65 
HSPA1A 
Heat shock 70 kDa protein 
1A 
0.27 
0.02 0.07 0.91 0.32 
HSPA8 
Heat shock cognate 71 kDa 
protein 
0.20 
0.06 0.78 0.51 0.51 
HSPB1 Heat shock protein beta-1 
0.37 
0.015 0.10 0.48 0.9 
HSPD1 
60 kDa heat shock protein, 
mitochondrial 
0.74 
0.72 0.33 0.50 0.40 
AIMP1 
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 1 
0.10 
0.07 0.60 0.96 0.09 
CDC37 Hsp90 co-chaperone Cdc37 
0.36 
0.09 0.58 0.11 0.34 
CLU Clusterin 
0.16 
0.88 0.76 0.69 0.72 
DNAJB1 
DnaJ homolog subfamily B 
member 1 
0.80 
0.08 0.23 0.38 0.60 
MAPKAPK2 
MAP kinase-activated 
protein kinase 2 
0.65 
0.37 0.64 0.67 0.50 
MAPKAPK5 
MAP kinase-activated 
protein kinase 5 
0.04 
0.04 0.27 0.83 0.07 
PPID 
Peptidyl-prolyl cis-trans 
isomerase D 
0.24 
0.17 0.70 0.94 0.94 
PPP3CA 
Serine/threonine-protein 
phosphatase 2B catalytic 
subunit alpha isoform 
0.28 
0.72 0.056 0.25 0.27 
STIP1 
Stress-induced-
phosphoprotein 1 
0.57 
0.10 0.66 0.006 0.09 
STUB1 
E3 ubiquitin-protein ligase 
CHIP 
0.01 
0.78 0.60 0.48 0.57 
TLR4 Toll-like receptor 4 0.30 0.76 0.33 0.82 0.40 
TLR4:MD-2 
complex 
Toll-like receptor 4 in 
complex with MD-2 
0.48 
0.05 0.72 0.52 0.19 
HSP 90a/b HSP90 dimer 
0.20 
0.70 0.57 0.44 0.35 
CD274 
Programmed cell death 1 
ligand 1 
0.54 
0.97 0.88 0.98 0.90 
EPHA2 Ephrin type-A receptor 2 
0.82 
0.32 0.03 0.50 0.07 
SMAD3 
Mothers against 
decapentaplegic homolog 3 
0.88 
0.008 0.75 0.29 0.39 
UBE2G2 
Ubiquitin-conjugating 
enzyme E2 G2 
0.006 
0.83 0.90 0.76 0.50 
UBE2L3 
Ubiquitin-conjugating 
enzyme E2L 3 
0.66 
0.09 0.37 0.04 0.27 
UBE2N 
Ubiquitin-conjugating 
enzyme E2 N 
0.80 
0.07 0.21 0.006 0.09 
UCHL1 
Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 
0.46 
0.37 0.73 0.69 0.30 
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Supplementary figure 3. Proteins that did not differ either between T2D and control subjects or during the post hypoglycemia time course. 
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Supplementary figure legends 
Supplementary Figure 1. Schematic figure showing an overview of interactions between 
HSP and associated proteins that are differentially expressed in response to 
hypoglycemia. These interactions decide the fate of the downstream signaling pathway. The 
HSP and associated proteins interact with the cell surface receptors and or with each other 
in response to different stimuli, including accumulated unfolded/misfolded proteins, 
hormones and cellular/environmental stress and regulate different molecules affecting a 
spectrum of biological functions such as apoptosis, autophagy, cell migration and alterations 
in the immune response.  The pathways depicted in the figure are the general pathways of 
HSP related signaling and are not restricted to a certain tissue or cell type.
Schematic created using Biorender (https://biorender.com)
HSP90 alpha (HSP90AA1, HSP90AB1, HSP90 beta, HSP 90a/b HSP90 dimer); 
HSPA1A, Heat shock 70 kDa protein 1A; HSPA8 Heat shock cognate 71 kDa protein ; 
HSPB1 Heat shock protein beta-1; HSPD1, 60 kDa heat shock protein, mitochondrial; 
AIMP1, Aminoacyl tRNA synthase complex-interacting multifunctional protein 1; CDC37 
Hsp90 co-chaperone Cdc37; CLU, Clusterin; DNAJB1, DnaJ homolog subfamily B member 
1; MAPKAPK2, MAP kinase-activated protein kinase 2; MAPKAPK5, MAP kinase-activated 
protein kinase 5; PPID, Peptidyl-prolyl cis-trans isomerase D; PPP3CA, Serine/threonine-
protein phosphatase 2B catalytic subunit alpha isoform; STIP1, Stress-induced-
phosphoprotein 1; TLR4, Toll-like receptor 4; TLR4:MD-2 complex, Toll-like receptor 
4 in complex with MD-2; CD274, Programmed cell death 1 ligand 1; EPHA2, Ephrin 
type-A receptor 2; SMAD3, Mothers against decapentaplegic homolog 3; E1, 
Ubiquitin activating enzyme; E2, Ubiquitin conjugating enzymes 2 (UBE2G2, Ubiquitin-
conjugating enzyme E2 G2; UBE2L3, Ubiquitin-conjugating enzyme; UBE2N,Ubiquitin-
conjugating enzyme E2 N); UCHL1, Ubiquitin carboxyl-terminal hydrolase isozyme L1; 
E3, Ubiquitin ligases; STUB1, E3 ubiquitin-protein ligase CHIP; NFB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; AKT, 
Protein kinase B,   HSF, heat shock factors; SNO, S-Nitrosylation; P38 MAPK, p38 mitogen-
activated protein kinases; Bcl-xL, B-cell lymphoma-extra large; LRP1, Low density 
lipoprotein receptor-related protein 1; TGFR, Transforming growth factor beta receptors; IR, 
Insulin receptor; IRS1, Insulin receptor substrate 1. 
Supplementary Figure 2. The comparison of blood glucose levels at baseline, at 
hypoglycaemia and post-hypoglycaemia up to 24 h. Blood sampling was performed at 
baseline (BL), at hypoglycaemia (0 min) and post-hypoglycaemia (0.5, 1, 2, 4 and 24 h) for 
controls (white circles) and for type 2 diabetes (T2D) (black squares). At BL, blood sugar (BS) 
was 7.5 ± 0.4 mmol/l (for T2D) and 5.0 ± 0.1 mmol/l (for control, C). Insulin was infused (at 
a rate of 2 mU/ml/Kg body weight) by hyperinsulinemic euglycemic clamp. At hypoglycemia, 
BS was 2.0 ± 0.03 mmol/l (for T2D) and 1.8 ± 0.05 mmol/l (for controls).  
Supplementary Figure 3. Circulatory HSP and related proteins that did not differ with 
hypoglycemia or between T2D and controls. Proteomic (Somalogic) analysis was 
undertaken to determine the plasma levels of HSP related proteins, Toll-like receptor 4 (TLR4) 
(A), Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) (B), Heat shock protein 
90AA1 (HSP90A1A) (C), Programmed cell death 1 ligand 1 (CD274) (D) at baseline (BL) 
during and after iatrogenic induction of hypoglycemia for control (C) and type 2 diabetes (T2D) 
subjects.  Blood sampling was performed at BL, at hypoglycemia (0 min) and post-
hypoglycemia (0.5-hour, 1-hour, 2-hours, 4-hours and 24-hours) for controls (white circles) 
and for T2D (black squares). 
Supplementary Figure 4. Changes of circulatory pro-inflammatory and anti-
inflammatory cytokines in response to hypoglycemia in control subjects and subjects with 
T2D. Proteomic (Somalogic) analysis was undertaken to determine the plasma levels of HSP 
related proteins, Interleukin 6 (IL-6) (A), Interleukin 10 (IL-10) (B), Interleukin 1A (IL-1A) 
(C), Interleukin 12 (IL-12) (D), Interferon gamma (IFN gamma) (E), TNF alpha (TNF alpha) 
(F) at baseline (BL), during and after iatrogenic induction of hypoglycemia for control (C) and
type 2 diabetes (T2D) subjects.  Blood sampling was performed at BL, at hypoglycemia (0 
min) and post-hypoglycemia (0.5-hour, 1-hour, 2-hours, 4-hours and 24-hours) for controls 
(white circles) and for T2D (black squares). Correlations of plasma levels of IL-6 at 2-hours 
post-hypoglycemia with HSP70 (G) and CDC37 (H).  
